Thousands more patients to access second ground-breaking antiviral

Thousands more patients to access second ground-breaking antiviral Thousands more vulnerable people in England are now eligible to receive the UK’s second oral antiviral treatment for COVID-19.

Paxlovid has been added to the PANORAMIC national study, the UK’s fastest-ever recruiting clinical trial of its kind, which is run by the University of Oxford in close collaboration with GP hubs. Department of Health and Social Care